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Background: Schizophrenia and bipolar disorder (BD) are psychiatric diseases that are commonly managed with
antipsychotics. Treatment pathways are highly variable and no universal treatment guidelines are available. The primary
objective of the Italian Burden of Illness in Schizophrenia and BD (IBIS) study was to describe pharmaco-utilisation of
antipsychotic treatments and characteristics of patients affected by schizophrenia or BD. A secondary objective was to
describe costs of illness for patients with schizophrenia or BD.
Methods: IBIS was a multicentre, real-world, retrospective, observational cohort study based on data obtained from
administrative databases of 16 Local Health Units in Italy (~7.5 million individuals). Patients with schizophrenia or
BD ≥18 years of age treated with antipsychotics between 1 January 2008 and 31 December 2009 were included in
the primary analysis. Pharmaco-utilisation data were gathered over a follow-up period of 12 months.
Results: Patients with schizophrenia and BD received a wide variety of antipsychotic medications. The proportion
of patients on antipsychotic monotherapy was 68% in patients with schizophrenia and 70% in patients with BD. In
patients with schizophrenia, ~1/3 of patients receiving antipsychotic monotherapy also received mood stabilisers
and/or antidepressants (34.7%) compared with over half of those on antipsychotic polytherapy (52.2%). In patients
with BD, use of mood stabilisers and/or antidepressants was even higher; 76.9% of patients receiving antipsychotic
monotherapy also received mood stabilisers and/or antidepressants compared with 85.5% of patients on antipsychotic
polytherapy. Switch therapy was more frequent in patients with BD than in patients with schizophrenia, whereas add-on
therapy was more frequent in patients with schizophrenia than in patients with BD. The mean total disease-related cost
per patient per annum was higher in patients with schizophrenia (€4,157) than in patients with BD (€3,301). The number
and cost of hospitalisations was higher in patients with BD, whereas the number and cost of nursing home stays was
higher in patients with schizophrenia.
Conclusion: Use of administrative databases has permitted retrieval of comprehensive information about therapeutic
pathways, diagnostic history and costs in patients affected by schizophrenia or BD. A need for personalised treatment
pathways has been described.
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Schizophrenia is a serious psychiatric disease with a high
mortality risk compared with the general population
(3.8-fold increase) [1] and is associated with greater co-
morbidity [2] and social exclusion [3]. With a prevalence
of approximately four to seven per 1,000 persons [4],
schizophrenia accounts for approximately 2.5% of total
health care resources [5].
Bipolar disorder (BD) is the seventh most common
global cause of disability for males and the eighth most
common for females [6]. It affects approximately 1% of
the world’s adult population and also has a high mortal-
ity rate [7]. Approximately 10–25% of patients suffering
from BD attempt suicide, with a success rate of almost
0.4% per year [7,8].
Antipsychotic drugs are the mainstay of drug treatment
of schizophrenia and BD, including first-generation agents
such as haloperidol and second-generation agents such as
olanzapine, risperidone and quetiapine, with many differ-
ent drugs and regimens available globally [9-13]. An
observational study in Italy, which examined patient
characteristics and their pattern of care in 1,330 patients
scheduled for discharge from acute psychiatric inpatient
facilities, showed that the majority of patients, of which
approximately half had schizophrenia or BD, were taking
two or more drugs [14]. Treatment is tailored to
an individual patient based on their clinical profile
and comorbidities [15,16]; concomitant medication with
anticonvulsants, mood stabilisers, anticholinergics, anti-
depressants and benzodiazepines is common [12,13].
Treatment pathways are highly variable and, as yet, no
universal treatment guidelines are available [17-21].
Furthermore, application of the selected guidelines that do
exist is highly dependent on the quality of the methodology
used in their development, which is ultimately limited by
financial resources [22]. The use of antipsychotic and anti-
depressant medication has increased in recent years [23]
and this could be ascribed to a number of factors including
the reduced stigma attached to mental health conditions,
worsening economic conditions and the occurrence of
natural disasters [23,24].
The Italian Burden of Illness in Schizophrenia and BD
(IBIS) study was conducted to describe the pharmaco-
utilisation of antipsychotic treatments in clinical prac-
tice, the characteristics of patients using these drugs and
the costs associated with schizophrenia and BD to the
Italian health service. At present, there are no studies in
Italy showing the economic impact of these conditions.
The primary objective of the IBIS study was to describe
the pharmaco-utilisation of antipsychotics (including
typical and atypical) and the characteristics of patients
affected by schizophrenia or BD in Italy. A secondary
objective was to describe the costs of illness for patients
with schizophrenia or BD. A further secondary objective,to describe treatment adherence and costs in patients who
switched from quetiapine immediate release to quetiapine
extended release, will be reported separately.
Methods
Study design and data sources
IBIS (ClinicalTrials.gov Identifier: NCT01392482) was a
multicentre, real-world, retrospective, observational, co-
hort study of pharmaco-utilisation data obtained from the
administrative databases of Local Health Units (LHUs) in
Italy for patients with schizophrenia or BD.
Patients were enrolled from the administrative data-
bases of 16 LHUs (approximately 7.5 million health-
assisted individuals). As a point of delivery for the Italian
National Health System, each LHU has an information
network that routinely measures expenditure related to
the dispensing of medications to registered patients. Such
databases are used conventionally to record the amounts
that pharmacies are entitled to receive from the LHU
in respect to medications reimbursable through public
finances and dispensed free of charge. Prescriptions
are attributed to each individual patient via a personal
health number.
The databases used were: (i) the Health-assisted Subjects’
Database, containing patients’ demographic data; (ii) the
Medications Prescription Database, providing information
for each prescription such as the prescribing physician’s
number, the Anatomical-Therapeutic-Chemical (ATC) code
of the drug purchased, the number of packs, the number of
units per pack, the dosage, the unit cost per pack and the
prescription date; (iii) the Hospital Discharge Database,
which includes the date of the hospitalisation and dis-
charge, admission and discharge wards, main and second-
ary discharge diagnosis, cost of the hospitalisation, based
on Diagnosis Related Group (DRG) classification; (iv) the
Mental Health Information System, which includes the
diagnosis of the patient and nursing home accesses and
psychiatric visits and related costs; (v) the Specialist Out-
patient Services Database which includes information on
outpatient services, dates and reimbursement costs, and
(vi) the No Charges Database which includes information
on free-of-charge services and dates.
The personal health number permitted electronic linking
between all databases, allowing information on medication
refills to be integrated with the patients’ date of birth, gen-
der, any record of hospitalisation, diagnostic test and
specialist visit. In order to guarantee patient privacy, each
subject was assigned an anonymous, unambiguous numeric
code. No identifiers related to patients were provided
to the researchers. The study was approved by the local
Ethics Committee in each participating LHU as follows:
USL Arezzo, ASL Bergamo, ASL Bolzano, ASL Ferrara,
ASL Firenze, USL Forlì, ASL Lecce, ASL Lecco, ASL
Matera, ASL Monza e Brianza, ASL Piacenza, ASL
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Roma D, ASL Teramo, ASL RM/D, ASL Udine. The
study was conducted in accordance with the Declaration
of Helsinki and Good Publication Practice.
Participants
Patients aged ≥18 years with a diagnosis of schizophrenia
(International Classification of Disease [ICD]10 F20, ICD9
295.XX) or BD (ICD10 F30–F31, ICD9 296.XX excluding
296.2 and 296.3, depression) were enrolled. The phase of
BD was established using the ICD code. The diagnoses
were identified from two separate databases: the Mental
Health Information System and the Hospital Discharge
Database (primary or secondary diagnoses) during the
period preceding the enrolment date. The use of hospital
discharge records allowed inclusion of patients who did
not access the Mental Health Department, but who devel-
oped a recurrence and were therefore hospitalised.
Patients must have been registered with the LHU for the
year before enrolment until 31 December 2010 or until
they died, if earlier. Patients were enrolled regardless of
how long they had received treatment. Patients who were
transferred to another LHU during the period of observa-
tion were excluded, as were patients affected by schizo-
affective disorders.
Patients were enrolled if they had filled at least one
prescription for antipsychotics (ATC code N05A) between
1 January 2008 and 31 December 2009 (enrolment
period). The enrolment date was defined as the first
date on which a patient filled a prescription for an anti-
psychotic (the index date). Patients were characterised
with regard to age, sex, diagnosis, treatments received
and comorbidities during the year prior to enrolment.
Pharmaco-utilisation
Starting from the index date, patients were followed for
1 year and pharmaco-utilisation data collected from the
Medications Prescription Database, including the pro-
portion of patients receiving an antipsychotic (ATC
code: N05A); the proportion receiving concomitant cen-
tral nervous system drugs (ATC codes: other N) (special
attention was given to mood stabilisers [ATC code
N03A] and antidepressants [ATC code: N06A]; lithium
[ATC code N05AN] was considered as a mood stabil-
iser); and the individual antipsychotics prescribed and
the combinations used. Antipsychotic monotherapy was
defined as a treatment with one antipsychotic medica-
tion during the 1-year follow-up period. Antipsychotic
polytherapy was defined as treatment with more than
one antipsychotic medication during the 1-year follow-
up period including switch therapy, where the patient’s
treatment was changed during the follow-up period, and
add-on treatments where patients received two or more
antipsychotics simultaneously.Cost of illness and resources consumption
The costs to the health system were retrieved from the
Mental Health Information System, the Medications Pre-
scription Database, the Specialist Outpatient Services
Database and the Hospital Discharge Database and were
classified as either disease-related or unrelated to schizo-
phrenia and BD.
Disease-related costs considered all the services provided
by Mental Health Departments, in particular residential
access (nursing home, full day) and semi-residential access
(nursing home, half day). Disease-related outpatient
specialist services included functional assessment (global,
segmental, monofunctional), graduated psycho-behavioural
assessment, clinical psychological interviews, psychiatric
evaluation, psychiatric evaluation for control, psycho-
therapy (individual, family, group) and psychodiagnostic
examination. The approach proposed by Weiden et al.
[25], which takes into account a wide range of psychiatric
diagnosis codes, was used to ensure all related hospitalisations
were identified. Costs for hospitalisations were derived
from the DRG codes and for outpatient services, costs
were retrieved from regional tariffs.
Other disease-related costs considered included antipsy-
chotics and concomitant central nervous system drugs
(again, special attention was given to mood stabilisers and
antidepressants; the price at the time of purchase was
used).
Unrelated costs included all direct healthcare costs not
previously described (e.g. a cardiovascular hospitalisation,





A total of 12,943 patients were included in the dataset
for the primary analysis. The dataset included 7,457
patients with schizophrenia representing 58% of the study
population. The mean age of patients with schizophrenia
was 48 years (women 53 years; men 46 years) and 40%
were female.
Bipolar disorder
The dataset included 5,486 patients with BD representing
42% of the study population. The mean age of patients
with BD was 52 years (women 54 years; men 50 years)
and 59% were female. In patients with BD, 44.3% of
patients were in a mania phase, 23.5% in a mixed phase,
16.5% in a depressive phase and 15.8% were unspecified.
Pharmaco-utilisation
A large number of prescription behaviours were observed
(Figures 1, 2 and 3); across all patients with schizophrenia















































Figure 1 Antipsychotic pharmaco-utilisation in patients treated with antipsychotic monotherapy for A) schizophrenia and B) bipolar disorder.
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BD received other drug classes, in addition to anti-
psychotics, than patients with schizophrenia (76.9% versus
34.7%) (Figure 3). For patients receiving polytherapy, 644
combinations were observed. The five most frequent com-
binations accounted for <25% of all combinations for both
pathologies (Figure 2). In patients receiving antipsychotic
polytherapy, more patients with BD received other drug
classes, in addition to antipsychotics, than patients with
schizophrenia (85.5% versus 52.2%). Switch therapy was
more frequent in patients with BD (48%) than in patients
with schizophrenia (31%), whereas add-on therapy was
more frequent in patients with schizophrenia (69%) than























Figure 2 Antipsychotic pharmaco-utilisation in patients treated with antiSchizophrenia
The proportion of patients with schizophrenia receiving
treatment with a single antipsychotic (antipsychotic
monotherapy) was 68% (Figure 3). The most commonly
prescribed antipsychotic monotherapy for patients with
schizophrenia was olanzapine (25%), followed by
risperidone (18%) and haloperidol (16%) (Figure 1).
Patients with schizophrenia receiving treatment with
more than one antipsychotic (antipsychotic polytherapy)
were more likely to receive other classes of pharmaco-
logical therapy such as mood stabilisers and/or antidepressants
than those receiving antipsychotic monotherapy; in
patients treated with antipsychotic polytherapy, 52.2% re-





















































































Mood stabiliser Antidepressants Both None
Figure 3 Pharmaco-utilisation profile. *Antiepileptic mood stabilisers + lithium.
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(Figure 3).
Bipolar disorder
For patients with BD, the proportion on antipsychotic
monotherapy was 70% (Figure 3). The most commonly
prescribed antipsychotic monotherapy for patients with
BD was olanzapine (35%), followed by quetiapine (20%)
and risperidone (12%) (Figure 1). Patients with BD re-
ceiving antipsychotic polytherapy were also more likely
to receive other therapies such as mood stabilisers and/
or antidepressants than those receiving antipsychotic
monotherapy; in patients treated with polytherapy, 85.5%
received mood stabilisers and/or antidepressants com-
pared with only 76.9% treated with antipsychotic mono-
therapy (Figure 3).
Cost of illness and resources consumption
The mean total disease-related cost per patient per annum
was higher in patients with schizophrenia (€4,157) than in
patients with BD (€3,301) (Table 1). Treatment with anti-
psychotics accounted for approximately 25% of totaldisease-related costs for patients with schizophrenia, with
nursing home costs and hospitalisations contributing 43%
and 27% of total costs, respectively.
Similarly, the cost of antipsychotics accounted for
approximately 27% of total disease-related costs of BD;
however, nearly half of the total cost was due to hospita-
lisations (46.7%) whereas nursing home costs accounted
for only 15% (Table 1). These costs are reflected in the
resource consumption for each disease: a higher propor-
tion of patients with schizophrenia (18%) had a stay in a
nursing home as compared with only just 8% of patients
with BD. Furthermore, 26% of patients with BD were
hospitalised whereas fewer patients with schizophrenia
(18%) spent time in hospital (Table 2).
Discussion
Schizophrenia and BD are complex disorders requiring
more targeted and personalised treatment approaches
[15,16,18,26]. Treatment can be tailored to an individual
patient according to their current symptoms, history of
therapeutic and adverse effects, comorbidities and their
expectations [15,16]. A number of clinical guidelines
Table 1 Cost of illness
Schizophrenia Bipolar disorder
€, mean SD %* €, mean SD %*
Antipsychotics (N05A) 1,018.81 1,213.58 24.5% 880.31 1,000.24 26.7%
Other drugs (CNS) 98.21 228.52 2.4% 264.87 364.18 8.0%
Ambulatory services 128.85 372.64 3.1% 114.08 284.00 3.5%
Hospitalisations 1,128.01 3,779.11 27.1% 1,542.01 3,839.23 46.7%
Nursing home 1,783.56 6,173.32 42.9% 499.76 3,123.50 15.1%
TOTAL 4,157.44 3,301.03
*Percentage of total cost; SD, standard deviation; CNS, central nervous system.
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cians [17,27]. However, due to the complex nature of the
management of these diseases and differences in the
methodology used to create guidelines, recommenda-
tions are often conflicting [17-19]. Furthermore, our un-
derstanding of these disorders is constantly evolving and
as a result guidelines can quickly become obsolete [18].
Real-world evidence is crucial for psychiatrists from a
disease management perspective to aid the development
of treatment guidelines, as large sample sizes representa-
tive of the general patient population can provide greater
external validity than randomised controlled trials. The
availability of population-wide databases is a preliminary
and essential requirement for capturing real-world evi-
dence and for the creation of an evidence-based research
and management system [28,29]; although such data
sources remain limited. To address this, epidemiological re-
searchers have sought to utilise alternative data sources in-
cluding medical and pharmacy claims databases similar to
the administrative databases held by Italian LHUs [30-32].
Healthcare claims databases have many advantages for
drug utilisation and economic research. These include a
reliably representative picture of the clinical and treat-
ment history of the monitored cohorts, the long dur-
ation of observation periods, the high generalisability of
the results obtained and reasonable utilisation costsTable 2 Resources consumption
Schizophrenia (n
Hospitalisations, pts (n,%, SD) 1,332
Hospitalisations, total 2,797
Hospitalisations (mean ± SD) 0.38
Length of stay (days, total) 13,325
Length of stay per hospital (days, mean ± SD) 18.2
Length of stay per pts (days, mean ± SD) 1.8
Nursing home, pts (n,%, SD) 1,368
Length of stay (days, mean ± SD) 15.5
Pts, ≥ 1 psychiatric visits, pts (n,%, SD) 4,266
Psychiatric visits (mean ± SD) 5.3
Pts, patients; SD, standard deviation.[33-35]. The large sample size and clinical setting may
allow identification of previously undetected patterns of
association that can be analysed in further studies.
The IBIS study showed that during the 1-year retro-
spective follow-up, patients with schizophrenia received
a wide variety of antipsychotic medications, employed in
many different combinations. This variety of combinations
may be partially explained by a lack of Italian national
guidelines and physicians tailoring therapy to fit the indi-
vidual patient. A large number of the antipsychotic combi-
nations used to treat patients with schizophrenia were
inconsistent with those recommended in guidelines for
the treatment of schizophrenia, such as those developed
by the National Institute for Health and Care Excellence.
For example, haloperidol is not recommended for use in
combination with other antipsychotics due to an increased
risk of QTc prolongation in the heart electrical cycle. In
our study, as shown in Figure 2, haloperidol was used in
some of the most common combinations. A substantial
number of patients with schizophrenia received mood
stabilisers and/or antidepressants in addition to their main
antipsychotic therapy. Likewise, in patients with BD, a
wide variety of antipsychotic medications were used,
employed in various combinations and many also re-
ceived mood stabilisers and/or antidepressants. Again,
in a large number of cases, patients with BD were= 7,457) Bipolar disorder (n = 5,486)






18.3 (0.4) 441 8.0 (0.4)
51.9 4.2 25.2
57.2 (0.6) 3,207 58.5 (0.7)
16.2 4.9 11.8
Degli Esposti et al. BMC Psychiatry 2014, 14:282 Page 7 of 9
http://www.biomedcentral.com/1471-244X/14/282treated with antipsychotic combinations that are not
recommended by current treatment guidelines for patients
with BD. Based on our findings, we believe that there is a
clear need for personalised treatment guidelines and
recommendations, as although the current guidelines provide
a valuable framework for pharmacological treatment, by
their nature they are not appropriate for all patients. A
more flexible approach would allow treatment to be
tailored to patient characteristics and would more accurately
reflect current clinical practice.
Differences in clinical management between the two
diseases were evident. The cost of hospitalisations (e.g.
emergency treatment) for patients with BD was consid-
erably higher than in patients with schizophrenia, which
may be indicative of a less stable patient population
requiring acute/emergency care. This suggests there
may be some scope to reduce costs by implementing
changes to the clinical management of BD, possibly by
early intervention to help prevent a bipolar episode
escalating to a medical emergency. In another retrospective
study, significant differences in mental health-related
hospitalisations and costs were observed in patients with
BD who received different formulations of the same
drug, demonstrating how treatment choices can affect
costs [36]. A recent systematic literature review of elec-
tronic databases, which analysed the cost of illness
worldwide for BD, found that in-patient care or drugs
costs were the main cost drivers in several studies [37].
Similarly, in a claims database analysis in a commercially
insured population in the US, average claim costs per
patient with schizophrenia were more than four times
higher compared with a population without schizophrenia,
and costs were mostly driven by in-patient charges in newly
diagnosed patients [38]. Add-on therapy (simultaneous
administration of more than one antipsychotic medication)
was more frequent in the treatment of patients with
schizophrenia than in patients with BD, which could be
attributed to the availability of more well-defined diagnostic
criteria for schizophrenia [13]. Indeed, in a retrospective
study of US veteran databases, which described longitudinal
antipsychotic prescribing patterns in schizophrenia, multiple
prescribing pathways were observed and antipsychotic
polypharmacy was commonly used as initial treatment [39].
The proportion of patients with BD in the manic phase of
the disease was relatively high, possibly suggesting a selection
bias through use of antipsychotics. The high ratio of
patients with mania may affect the observed hospitalisation
rate which may not be representative of the overall BD
population. However, although antipsychotics are generally
indicated for mania some can also be given as adjunctive
treatment of bipolar depression or as part of maintenance
therapy. Alternatively, as some of the databases used
retrieved data from hospital records, patients in the mania
phase are more likely to be included, as patients withmania are hospitalised more often than patients in
the depressive phase [40-42]. However, the analysis also
included data from non-hospitalised sources such as
Medications Prescription Database and the Specialist
Outpatient Services Database.
Limitations
As this is a retrospective database study, associations
between drug regimens and clinical outcomes can be
assessed but causality cannot be inferred. Due to the
collection methods used, the robustness of the data is
dependent on the accuracy and extent of the informa-
tion recorded in the database. In addition, the data are
for the period 2009 to 2010 and so may not represent
the most up to date practice. Administrative claims data
in general are subject to potential coding errors and
inconsistencies and may be affected by the limitations of
clinical data. Moreover, in Italy diagnosis scales are
rarely used and recorded. Other limitations of using
administrative claims data are the exclusion of privately
treated patients and ambiguity over the target indication
of the therapy prescribed (some medications could have
been taken for indications other than schizophrenia or
BD, e.g. neuropathic pain, epilepsy, etc.).
Conclusions
The use of administrative databases has permitted re-
trieval of comprehensive information about therapeutic
pathways, diagnostic history and costs in patients affected
by schizophrenia or BD providing psychiatrists and deci-
sion makers with information about pharmaco-utilisation
of antipsychotic drugs. The wide variety of antipsychotic
medications and combinations used to treat schizophrenia
and BD observed in the IBIS study, reflects the evident
need for personalised treatment. Current treatment
guidelines are not suitable for all patients due to the
complex nature of these diseases and their management.
More targeted guidance that tailors treatment to patient
characteristics would aid the management of these
disorders.
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